Evolution of Acinetobacter baumannii infections and antimicrobial resistance. A review

Open access

Abstract

The emergence of multi-drug resistant Acinetobacter spp involved in hospital-acquired infections, once considered an easily treatable pathogen, is troublesome and an immense burden for the modern medical systems worldwide. In the last 20 years the medical community recorded an increase in the incidence and severity of these infections as therapeutic means tend to be less and less effective on these strains. The ability of these bacteria to rapidly develop resistance to antimicrobial agents by continuously changing and adapting their mechanisms, their ability to survive for long periods of time in the hospital environment and the multitude of transmission possibilities raises serious issues regarding the management of these complex infections. The future lies in developing new and targeted methods for the early diagnosis of A. baumannii, as well as in the judicious use of antimicrobial drugs. This review details the evolution of the pathogenicity of this microorganism, together with the changes that appeared in resistance mechanisms and the advancements in molecular testing for the early detection of infection.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Bueno-Cvanillas A Delgado-Rodriguez M et al. Influence of nosocomial infection on mortality rate in an intensive care unit. Crit Care Med 1994; 22(1):55-60

  • 2. Wilson DJ. Insights from genomics into bacterial pathogen populations. PLoS Pat-hog. 2012;8(9):e1002874.

  • 3. Nemec A Musilek M Mxinerova M etl al. Acinetobacter beijerinckii sp nov and Acinetobacter gyllenbergii sp nov. haemolytic organisms isolated from humans. Int J Syst Evol Microbiol 2009;59:118-124.

  • 4. Bouvet P. J. and P. A. Grimont. 1986. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov. Acinetobacter haemolyticus sp. nov. Acinetobacter johnsoniisp. nov. and Acinetobacter junii sp. nov. and emended description of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int. J. Syst. Bacteriol. 36:228-240.

  • 5. Jones CL Clancy M Honnold C et al. Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis 2015 61(2):145-54.

  • 6. Choi WS Kim SH et al. Nosocomial Outbreak of Carbapenem – Resistant Acientobacter baumannii in Intensive Care Units and Successful Outbreak Control Program. Journal of Korean Medical Science 2010;7:999-1004

  • 7. Wright MS Iovleva A Jacobs MR et al. Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Med 2016;8(1):26.

  • 8. Asif M Alvi IA Rehman SU. Insight to Acinetobacter baumannii:pathogenesis global resistance mechanisms of resistance treatment options and alternative modalities

  • 9. Peleg AY Seifert H Paterson D. Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Rev 2008;21(3):538-582

  • 10. Nemec A De Baere T Tjernberg I Vaneechoutte M van der Reijden TJ Dijkshoorn L. Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov. isolated from human clinical specimens. Int J Syst Evol Microbiol 2001;51(Pt 5):1891-9.

  • 11. Nemec A Dijkshoorn L Cleenwerck I De Baere T et al. Acinetobacter parvus sp. Nov. a small-colony-forming species isolated from human clinical specimens. Int J Syst Evol Microbiol 2003; 53(Pt4):1563-7.

  • 12. Carr E. L. P. Kampfer B. K. Patel V. Gurtler and R. J. Seviour. Seven novel species of Acinetobacter isolated from activated sludge. Int. J. Syst. Evol. Microbiol 2003. 53:953-963.

  • 13. Tjernberg I. and J. Ursing. Clinical strains of Acinetobacter classified by DNA-DNA hybridization. APMIS 1989;97:595-605.

  • 14. Garner-Smidt P Tjernberg I Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991; 29:277-282.

  • 15. Murray PR Baron EJ Pfaller MA Tenover FC Yolken RH. Manual of Clinical Microbiology 6th edition. Washington DC: American Society of Microbiology 1995:190-208.

  • 16. Hartstein AI Morthland VH Rourke JW Jr Freeman J Garber S Sykes R Rashad AL. Plasmid DNA fingerprinting of Acinetobacter calcoaceticus subspecies anitratus from intubated and mechanically ventilated patients. Infect Control Hosp Epidemiol 1990;11(10):531-8.

  • 17. Bou G Cerveró G Domínguez MA Quereda C Martínez-Beltrán J. PCR-based DNA fingerprinting (REP-PCR AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2000;6(12):635-43.

  • 18. Seifert H Dolzani L Bressan R van der Reijden T van Strijen B Stefanik D Heersma H Dijkshoorn L. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol. 2005;; 43(9):4328-35.

  • 19. Janssen P Coopman R Huys G Swings J Bleeker M Vos P Zabeau M Kersters K. Evaluation of the DNA fingerprinting method AFLP as an new tool in bacterial taxonomy. Microbiology. 1996; 142:1881-93.

  • 20. Al Sehlawi ZS Almohana AM Thahab AA. Isolation and Identification of Acinetobacter baumannii Clinical Isolates using Novel Methods. Journal of Babylon University 2014; 22:2-11.

  • 21. Lugtenberg B van Alphen L. Molecular architecture and functioning of the outer membrane of Escherichia coli and other gram-negative bacteria. Biochim Biophys Acta 1983. 737:51-115

  • 22. Pantophlet R Brade L Brade H. Identifi-cation of Acinetobacter baumannii Strains with Monoclonal Antibodies against the O Antigens of Their Lipopolysaccharides. Clinical and Diagnostic Laboratory Immunology 1999;6:323-329.

  • 23. Haseley SR Holst O Brade H. Structural and serological characterization of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter haemolyticus strain ATCC 17906. Eur J Biochem 1997;244:761-766.

  • 24. Haseley SR Holst O Brade H. Structural studies of the O-antigen isolated from the phenol-soluble lipopolysaccharide of Acinetobacter baumannii (DNA group 2) starin 9. Eur J Biochem 1998;251:189-194.

  • 25. Baig A Cabral TM Corbett CR. Development and characterization of monoclonal antibodies for rapid detection of Acinetobacter baumannii. Monoclon Antib Immunodiagn Immunother 2014;33(4):291-8.

  • 26. Thoma C Bacchi M Bedenic B Cornaglia G Mazzariol A. Evaluation of molecular and biochemical methods to detect carbapenemases-producing Acinetobacter baumannii. 2016

  • 27. Doi Y Murray GL Peleg AY. Acinetobacter baumannii: Evolution of Antimicrobial Resistance-Treatment Options. Semin Respir Crit Care Med 2015;36:85-98.

  • 28. Shimose LA Masuda E Sfeir M et al. Carbapenem-resistant Acinetobacter baumannii: concomitant contamination of air and environmental surfaces. Infect Control Hosp Epidemiol 2016;37(7):777–781.

  • 29. Tudor CA Boros C Petre R et al. Raspunsul imun in pneumonia cu Acinetobacter baumannii. Revista romana de boli infectioase 2016;19(1):16-21.

  • 30. Greene C Vadlamudi G Newton D Foxman B Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. Am J Infect Control 2016;44(5):e65-71.

  • 31. Moreira Silva G Morais L Marques L Senra V. Acinetobacter community-acquired pneumonia in a healthy child. Rev Port Pneumol 2012;18(2):96-8.

  • 32. Arodino I Zangirolami F Iemmi D Lanzoni M Cargnelutti M et al. Risk factors and epidemiology of Acinetobacter baumannii infections in a university hospital in Northern Italy: A case-control study.

  • 33. Zarrilli R. Acinetobacter baumannii virulence determinants involved in biofilm growth and adherence to host epithelial cells. Virulence 2016;1–2.

  • 34. Denton M Wilcox MH Parnell P et al. Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. Intensive Crit Care Nurs 2005;21(2)94-98.

  • 35. Orsi GB Franchi C Giordano A et al. Multidrug-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Chemother 2008;20(2):219-228.

  • 36. Gaynes R Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect Dis 2005;41:848-854.

  • 37. Qiu H Kuo Lee R Harris G van Rooijen N et al. Role of Macrophages in Early Host Resistance to Respiratory Acinetobacter baumannii Infection. PLoS One 2012;7(6): e40019.

  • 38. Valencia R Arroyo LA Conde M et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009;30(3):257-63.

  • 39. Pourhajibagher M Hashemi FB Pourakbari B Aziemzadeh M Bahador A. Antimicrobial Resistance of Acinetobacter baumannii to Imipenem in Iran: A Systematic Review and Meta-Analysis. Open Microbiol J 2016; 10():32-42.

  • 40. Marvig R L Johansen HK Molin S Jelsbak L.Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet. 2013

  • 41. Hua X Zhou Z Yang Q et al. Evolution of Acinetobacter baumannii In Vivo: International Clone II More Resistance to Ceftazidime Mutation in ptk. Front Microbiol 2017;8:1256.

  • 42. Bergogne-Bérézin E Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological clinical and epidemiological features. Clin Microbiol Rev 1996;9(2):148-65.

  • 43. Da Silva G Dijkshoorn L van der Reijden T van Strijen B Duarte A. Identification of widespread closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II. Clin Microbiol Infect. 2007 Feb; 13(2):190-195.

  • 44. Turton JF Kaufmann ME Warner M Coelho J Dijkshoorn L van der Reijden T Pitt TL. A prevalent multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect. 2004;58(3):170-9.

  • 45. 382. Naas T. B. Coignard A. Carbonne K. Blanckaert O. Bajolet C. Bernet X. Verdeil P. Astagneau J. C. Desenclos and P. Nordmann. 2006. VEB-1 extended-spectrum beta-lactamase-producing Acinetobacter baumannii France. Emerg. Infect. Dis.12:1214-1222.

  • 46. van Dessel H Dijkshoorn L van der Reijden T Bakker N Paauw A van den Broek P Verhoef J Brisse S. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol. 2004;155(2):105-12.

  • 47. Hujer KM Hamza NS Hujer AM et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother. 2005;49(7):2941–2948.

  • 48. Héritier C Poirel L Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. Clin Microbiol Infect. 2006 Feb; 12(2):123-30.

  • 49. Adams-Haduch JM Paterson DL Sidjabat HE et al. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008;52(11):3837–3843.

  • 50. Figueiredo S Poirel L Papa A Koulourida V Nordmann P. Over-expression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9. Antimicrob Agents Chemother. 2009;53(9):4045–4047.

  • 51. Urban C Go E Mariano N Rahal JJ. Interaction of sulbactam clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii. FEMS Microbiol Lett. 1995;125:193–198.

  • 52. Shaw KJ Rather PN Hare RS Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993;57(1):138–163.

  • 53. Liou GF Yoshizawa S Courvalin P Galimand M. Aminoglycoside resistance by ArmA-mediated ribosomal 16S methylation in human bacterial pathogens. J Mol Biol. 2006;359(2):358–364.

  • 54. Adams-Haduch JM Paterson DL Sidjabat HE et al. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008;52(11):3837–3843.

  • 55. Coyne S Rosenfeld N Lambert T Courvalin P Périchon B. Over-expression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Anti-microb Agents Chemother. 2010;54(10):4389–4393.

  • 56. Beceiro A Llobet E Aranda J et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55(7):3370–3379.

  • 57. Moffatt JH Harper M Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54(12):4971–4977.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 167 167 30
PDF Downloads 117 117 20